NCT07008638View on ClinicalTrials.gov

Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 7, 2025

Primary Completion Date

December 30, 2027

Study Completion Date

January 27, 2028

Conditions
Acute Myeloid LeukemiaTP53
Interventions
DRUG

Bortezomib

Bortezomib at assigned study dose in mg/m2 will be given subcutaneously on days 1, 4, 8, and 11

DRUG

CPX-351

CPX-351 given intravenously on day 1, 3, and 5

Trial Locations (1)

55455

RECRUITING

Masonic Cancer Center, Minneapolis

All Listed Sponsors
lead

Masonic Cancer Center, University of Minnesota

OTHER

NCT07008638 - Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML) | Biotech Hunter | Biotech Hunter